A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant Disorders
- Conditions
- Hematologic Malignancies
- Interventions
- Procedure: UCB and HPDSC
- First Posted Date
- 2008-01-17
- Last Posted Date
- 2012-04-10
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 6
- Registration Number
- NCT00596999
- Locations
- 🇺🇸
Louisiana State University Children's Hospital, New Orleans, Louisiana, United States
Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma
- Conditions
- Multiple Myeloma
- First Posted Date
- 2007-11-07
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Celgene
- Target Recruit Count
- 15
- Registration Number
- NCT00555100
- Locations
- 🇯🇵
Keio University Hospital, Tokyo, Japan
🇯🇵Niigata Cancer Center Hospital, Niigata, Japan
🇯🇵National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan
AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy
- First Posted Date
- 2007-10-22
- Last Posted Date
- 2019-11-06
- Lead Sponsor
- Celgene
- Target Recruit Count
- 637
- Registration Number
- NCT00547651
- Locations
- 🇺🇸
Northwest Alabama Cancer Center, Muscle Shoals, Alabama, United States
🇺🇸Cedars-Sinai Outpatient Cancer Center, Los Angeles, California, United States
🇺🇸Cancer Care Associates of Fresno Medical Group, Inc., Fresno, California, United States
Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2019-10-29
- Lead Sponsor
- Celgene
- Target Recruit Count
- 1052
- Registration Number
- NCT00540514
- Locations
- 🇺🇸
Comprehensive Blood and Cancer Center, Bakersfield, California, United States
🇺🇸Robert A. Moss, MD, FACP, Inc., Fountain Valley, California, United States
🇺🇸Mercy Hospital, Portland, Maine, United States
A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide
- Conditions
- Carcinoma, Small Cell
- Interventions
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 22
- Registration Number
- NCT00537511
- Locations
- 🇺🇸
Pennsylvania State University, Hershey, Pennsylvania, United States
🇺🇸Ireland Cancer Center, Case Western Reserve University, Division of Hematology/Oncology, Cleveland, Ohio, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
ABI-008 Trial in Patients With Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer
- First Posted Date
- 2007-09-18
- Last Posted Date
- 2019-11-14
- Lead Sponsor
- Celgene
- Target Recruit Count
- 85
- Registration Number
- NCT00531271
- Locations
- 🇺🇸
University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
- Conditions
- Myelodysplastic Syndromes (MDS)Chronic Myelomonocytic Leukemia (CMML)Acute Myelogenous Leukemia (AML)
- Interventions
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 133
- Registration Number
- NCT00528983
- Locations
- 🇺🇸
Institute for Translational Oncology Research IRB, Greenville, North Carolina, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Central Indiana Cancer Centers, Indianapolis, Indiana, United States
Prevention of Restenosis Following Revascularization
- Conditions
- Vascular Disease, Peripheral
- Interventions
- Drug: Nanoparticle Paclitaxel
- First Posted Date
- 2007-08-20
- Last Posted Date
- 2012-03-13
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 6
- Registration Number
- NCT00518284
- Locations
- 🇺🇸
Michigan Vascular Research Center, Flint, Michigan, United States
🇺🇸Lindner Clinical Trials Center, Cincinnati, Ohio, United States
🇺🇸UC Davis Medical Center, Ellison Ambulatory Care Center Cardiology Suite 3400, Sacramento, California, United States
AVIDA The Vidaza® (Azacitidine) Patient Registry
- Conditions
- Myelodysplastic Syndromes
- First Posted Date
- 2007-06-01
- Last Posted Date
- 2018-05-03
- Lead Sponsor
- Celgene
- Target Recruit Count
- 479
- Registration Number
- NCT00481273
- Locations
- 🇺🇸
AVIDA Registry Help, Kansas City, Missouri, United States
A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2007-05-25
- Last Posted Date
- 2011-11-03
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 150
- Registration Number
- NCT00478777
- Locations
- 🇩🇪
Abt. Innere Medizin I , Hämatologie / Onkologie, Universitätsklinikum Freiburg, Freiburg, Germany
🇩🇪EPS - Early Phase Solutions GmbH, Jena, Germany
🇩🇪Direktor der Klinik f. Hämatologie, Universitätsklinikum Essen, Essen, Germany